San Diego, CA – December 18, 2007 – Ambrx Inc. today announced that it has entered into a global, strategic collaboration with Merck & Co. Inc. to develop a novel therapeutic protein with biological properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic diso… Read More

San Diego, CA – December 17, 2007 – Privately held Ambrx Inc. today announced that it has entered into a collaboration with Eli Lilly and Company (NYSE:LLY) to discover and develop novel treatments in several therapeutic areas, including metabolic diseases, central nervous system disorders and other diseases. … Read More

San Diego, CA – July 24, 2007 – Ambrx Inc. today announced the appointment of Stephen Kaldor, Ph.D., as President and Chief Executive Officer. Kaldor, who also joins the company’s Board of Directors, has nearly two decades of success in multiple assignments in emerging biotechnology an… Read More

San Diego, CA – June 19, 2007 – Ambrx Inc. announced today a collaboration with Merck Serono, an affiliate of Merck KGaA, Darmstadt, Germany, to develop and commercialize Ambrx’s long-acting growth hormone products. The collaboration will focus initially on the development of ARX201, th… Read More

San Diego, CA – February 12, 2007 – Ambrx Inc. announced today that it has initiated a Phase I/II clinical trial of ARX201, a novel, next-generation human growth hormone product candidate. The Phase I/II dose-finding study in adult patients with growth hormone deficiency will investigate the … Read More